Abstracts tagged "Adverse events"

Abstract Number: 1492 • 2016 ACR/ARHP Annual Meeting
Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study
Jeffrey Curtis¹, Fenglong Xie², Lang Chen² and Huifeng Yun³, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Serious infection events (SIE) and myocardial infarction (MI) are among the most concerning adverse events that occur in rheumatoid arthritis (RA) patients. The role…
Abstract Number: 2178 • 2016 ACR/ARHP Annual Meeting
Statin Use and Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study with Propensity Score-Matching
Una E. Makris^1,2, Carlos A. Alvarez^2,3,4, Eric M. Mortensen^2,4 and Ishak Mansi^2,4, ¹Rheumatology, UT Southwestern Medical Center, Dallas, TX, ²VA North Texas Health Care System, Dallas, TX, ³Texas Tech University Health Science Center, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Given conflicting evidence regarding statin use and the relationship with musculoskeletal conditions, and the rising disability and societal/personal repercussions associated with both osteoarthritis (OA)…
Abstract Number: 2332 • 2016 ACR/ARHP Annual Meeting
Midterm Outcome of Modular Metal-on-Metal Total Hip Arthroplasty
Hiroki Wakabayashi¹, Masahiro Hasegawa², Toshio Yamaguchi³, Yohei Naito⁴ and Akihiro Sudo⁵, ¹Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Japan, ²Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, Japan, ³Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Japan, ⁴Department of Orthopaedic Surgery, Graduate School of Medicine, Mie University, Tsu City, Mie, Japan, ⁵Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu City, Japan
Background/Purpose: Wear, osteolysis, and late aseptic loosening associated with ultrahigh-molecular-weight polyethylene components used in total hip arthroplasties (THA) have led to increased interest in metal-on-metal…
Abstract Number: 2444 • 2016 ACR/ARHP Annual Meeting
Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis
Emily Fishman¹, Kathryn H. Dao² and John J. Cush³, ¹Texas A&M HSC College of Medicine, Dallas, TX, ²Texas Health, Dallas, TX, ³Baylor Research Institute, Dallas, TX
Background/Purpose: Pregnancy is often encountered in women who have inflammatory arthritis (IA), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile arthritis (JIA) or ankylosing…
Abstract Number: 2547 • 2016 ACR/ARHP Annual Meeting
Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis
Frank Buttgereit¹, Jonna Amann², Friederike Breitenfeldt³, Dörte Huscher⁴, Johannes WJ Bijlsma⁵ and Johannes WG Jacobs⁶, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁴Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ⁵ARC, Amsterdam, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Glucocorticoids (GCs) are frequently and often chronically used for the treatment of rheumatoid arthritis (RA) and other immune diseases and vasculitis. An estimated 0.8–1.2%…
Abstract Number: 2595 • 2016 ACR/ARHP Annual Meeting
Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry
Arthur F. Kavanaugh¹, Jamie Geier², Clifton Bingham III³, Connie Chen², George W. Reed^4,5, Katherine C. Saunders⁴, Yan Chen⁶, Andrew Koenig⁶, Laura Cappelli⁷, Jeffrey D. Greenberg^4,8 and Joel M. Kremer⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Pfizer, Inc., New York, NY, ³Johns Hopkins University, Baltimore, MD, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Pfizer, Inc., Collegeville, PA, ⁷Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸NYU School of Medicine, New York, NY, ⁹Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: An interim analysis of a prospective observational 3+ year study, embedded within the US Corrona Rheumatoid Arthritis (RA) registry (14 years and ongoing), was…
Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting
Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry
Kaleb Michaud^1,2, Sofia Pedro², TA Simon³, Frederick Wolfe² and Rebecca Schumacher², ¹University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…
Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Bertrand Lioger^1,2, Fanny Hennekinne¹, Marie-Sara Agier³, Annie-Pierre Jonville-Bera^3,4 and François Maillot^1,5, ¹Internal Medicine, Tours University Hospital, Tours, France, ²GICC UMR 7292, University François Rabelais, Tours, France, ³Clinical Pharmacology, Tours University Hospital, Tours, France, ⁴Regional Pharmacovigilance Center, Tours University Hospital, Tours, France, ⁵INSERM U1069, University François Rabelais, Tours, France
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…
Abstract Number: 2109 • 2015 ACR/ARHP Annual Meeting
Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)
Na Lu¹, Sharan K. Rai², Jeewoong Choi³ and Hyon K. Choi¹, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ³Massachusetts College of Pharmacy and Health Sciences, Boston, MA
Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy for gout (>95% of treated cases); however, it is associated with the rare but potentially fatal…
Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-Î± Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Meghna Jani¹, William G Dixon², Lianne Kearsley-Fleet³, Ian N. Bruce^4,5, Hector Chinoy^6,7, Anne Barton^6,8, Mark Lunt⁹, Kath Watson³, Deborah P.M. Symmons¹, Kimme L. Hyrich³ and on behalf of the BSRBR-RA, ¹Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁸NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester Foundation Trust and University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁹Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…
Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Ashima Makol¹, Steven R. Ytterberg⁴, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register
Pongthorn Narongroeknawin¹, Wanruchada Katchamart², Parawee Suwannalai³, Nuntana Kasitanon⁴, Tasanee Kitumnuaypong⁵, Ajanee Mahakkanukrauh⁶ and Boonjing Siripaitoon⁷, ¹Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand, ⁶Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, ⁷Division of Rheumatology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…
Abstract Number: 2167 • 2015 ACR/ARHP Annual Meeting
Application of Combined Reporting of Benefit and Harm (OMERACT 3×3 methodology) to the Rheumatoid Arthritis Comparison of Active Therapies Trial
Maarten Boers^1,2, Sarah Leatherman³, James R. O'Dell⁴ and Jeffrey R. Curtis⁵, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, VU University Medical Center, Amsterdam, Netherlands, ³MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Birmingham VAMC, Birmingham, AL
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Initiative has suggested an analysis of the occurrence of benefit and harm in trials simultaneously, at the individual…
Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Cheryl Barnabe¹, Yufei Zheng², Arto Ohinmaa², Brenda Hemmelgarn³, Gilaad Kaplan⁴, Liam Martin⁵ and Walter Maksymowych⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health Economics, Edmonton, AB, Canada, ³Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Medicine, Medicine, University of Alberta, Edmonton, AB, Canada
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…
Abstract Number: 552 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab
Gerd Burmester¹, Gurjit S. Kaeley², Arthur Kavanaugh³, Cem Gabay⁴, Daryl MacCarter⁵, Peter Nash⁶, Tsutomu Takeuchi⁷, Anabela Cardoso⁸, Shufang Liu⁹, Hartmut Kupper¹⁰ and Jasmina Kalabic¹¹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of Florida, Jacksonville, FL, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ⁶Department of Medicine, University of Queensland, Brisbane, Australia, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸Torre Oriente, AbbVie, Lisboa, Portugal, ⁹Immunology Development, AbbVie, North Chicago, IL, ¹⁰AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Combination treatment of rheumatoid arthritis (RA) with methotrexate (MTX)+adalimumab (ADA) has been shown to be more effective than ADA monotherapy. However, MTX is associated…

« Previous Page
1
…
4
5
6
7
8
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].